文献速递炎症性肠病

基于全球临床试验4.4年数据评估托法替布治疗溃疡性结肠炎的安全性

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-11-23

本文报告托法替布治疗中重度溃疡性结肠炎的综合安全性分析。维持队列中托法替布10mg每日两次的带状疱疹感染发生率显著高于安慰剂,总体队列(84%平均剂量为10mg每日两次)各不良事件发生率已列出。结论认为除带状疱疹感染发生率较高外,托法替布安全性特征与类风湿关节炎及生物制剂治疗溃疡性结肠炎患者相似,但随访时间相对较短。

要点

  • 维持队列中托法替布10mg每日两次的带状疱疹感染发生率显著高于安慰剂。
  • 总体队列中84%患者平均剂量为托法替布10mg每日两次。
  • 除带状疱疹感染外,托法替布安全性特征与类风湿关节炎及生物制剂治疗溃疡性结肠炎患者相似。

核心结论

  • 在托法替布治疗中重度溃疡性结肠炎的安全性分析中,观察到带状疱疹感染与剂量相关。
  • 尽管随访时间相对较短,除带状疱疹感染发生率较高外,托法替布治疗溃疡性结肠炎的安全性特征与类风湿关节炎患者及生物制剂治疗溃疡性结肠炎患者报告的安全性相似。

研究设计与样本

  • 分析三项队列:诱导队列(2期和3期诱导研究,n=1220)、维持队列(3期维持研究,n=592)和总体队列(在2期、3期或开放标签长期扩展研究中接受托法替布5mg或10mg每日两次的患者,n=1157,暴露1613患者年)。
  • 评估选定不良事件的发生率(每100患者年暴露的事件患者数)。

主要发现

  • 维持队列中,托法替布5mg每日两次的带状疱疹感染发生率为2.1(95%CI 0.4-6.0),托法替布10mg每日两次为6.6(95%CI 3.2-12.2),安慰剂为1.0(95%CI 0.0-5.4);10mg每日两次组较安慰剂组统计学显著升高。
  • 总体队列(84%接受平均剂量托法替布10mg每日两次)中,死亡发生率为0.2(95%CI 0.1-0.6),严重感染为2.0(95%CI 1.4-2.8),机会性感染为1.3(95%CI 0.8-2.0),带状疱疹感染为4.1(95%CI 3.1-5.2),恶性肿瘤(不包括非黑色素瘤皮肤癌)为0.7(95%CI 0.3-1.2),非黑色素瘤皮肤癌为0.7(95%CI 0.3-1.2),主要不良心血管事件为0.2(95%CI 0.1-0.6),胃肠道穿孔为0.2(95%CI 0.0-0.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 随访时间相对较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tofacitinib is an oral, small-molecule inhibitor of JAK approved in several countries for the treatment of ulcerative colitis (UC). We report integrated safety analyses of tofacitinib-treated patients with moderate to severe UC. METHODS: Patients receiving placebo or tofacitinib (5 or 10 mg) twice daily were analyzed as 3 cohorts: induction (phase 2 and 3 induction studies, n = 1220), maintenance (phase 3 maintenance study, n = 592), and overall (patients receiving tofacitinib 5 or 10 mg twice daily in phase 2, phase 3, or open-label, long-term extension studies, n = 1157; 1613 patient-years' exposure). Incidence rates (IRs; patients with events per 100 patient-years of exposure) were evaluated for select adverse events. RESULTS: In the maintenance cohort, IRs for select adverse events were similar among treatment groups, except for a numerically higher IR of herpes zoster infection among patients who received tofacitinib 5 mg twice daily (2.1; 95% CI, 0.4-6.0) and statistically higher IR among patients who received tofacitinib 10 mg twice daily (IR, 6.6; 95% CI, 3.2-12.2) vs placebo (IR, 1.0, 95% CI, 0.0-5.4). For the overall cohort (84% received average dose of tofacitinib 10 mg twice daily), IRs were: death, 0.2 (95% CI, 0.1-0.6); serious infections, 2.0 (95% CI, 1.4-2.8); opportunistic infections, 1.3 (95% CI, 0.8-2.0); herpes zoster infection, 4.1 (95% CI, 3.1-5.2); malignancy (excluding non-melanoma skin cancer), 0.7 (95% CI, 0.3-1.2); non-melanoma skin cancer, 0.7 (95% CI, 0.3-1.2); major adverse cardiovascular events, 0.2 (95% CI, 0.1-0.6); and gastrointestinal perforations, 0.2 (95% CI, 0.0-0.5). CONCLUSIONS: In safety analyses of patients with moderate to severe UC treated with tofacitinib, we observed a dose relationship with herpes zoster infection. Although follow-up time was relatively short, the safety profile of tofacitinib for patients with UC appeared similar to that reported for patients with rheumatoid arthritis and for patients with UC treated with biologic agents, except for the higher IR of herpes zoster infection. ClinicalTrials.gov, no: NCT00787202, NCT01465763, NCT01458951, NCT01458574, and NCT01470612.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Panés J, D'Haens GR, et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2018. PMID: 30476584. doi:10.1016/j.cgh.2018.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。